A Multicenter Evaluation of Blood Purification with Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19: A Preliminary Report
Of the 53 Seraph 100 patients included in the analysis, 1 patient experienced transient hypotension at the start of the treatment which required a brief period of vasopressor support.
These data suggest that broad spectrum, pathogen agnostic, extracorporeal blood purification therapies can be safely and effectively deployed to meet new pathogen threats as an adjunct to standard treatments while awaiting pharmacologic therapies and/or vaccines.
I was prepping for a panel discussion with medical students on death and dying. Had to get some thoughts together based on my experience as a military intensivist so I thought I would share.
I’ve experienced my share of death. Of course the typical “taking terminal patients through the dying process” kind of stuff that every internist and intensivist deals with…
I just saw this thread by @MarkHoofnagle and feel compelled to respond to clarify some things.
Disclaimers: I am not an ID expert. I am a Medical Intensivist in the Military. These are not the official views of the DoD. Just my personal opinions. No financial COIs.
I have participated only as a site-AI but I have participated in investigator meetings since the inception of this trial so I have *some* inside knowledge.
2/
First off, this trial was conceived and protocol approved before our very first US case back in February. It is funded by NIAID. Not Gilead. Remdesivir was chosen because of its potential. Not financially motivated.